Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 432 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Methotrexate Clear all
Completed Phase 2 Interventional Results available

Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

NCT01848457
View directory record Official record
Conditions
Osteosarcoma, Nephrotoxicity, Ototoxicity
Interventions
Pantoprazole, High-dose methotrexate infusion duration
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Jun 26, 2026, 2:41 AM EDT
Terminated Phase 3 Interventional Results available

Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

NCT01014767
View directory record Official record
Conditions
Brain Cancer, Choroid Plexus Tumors
Interventions
Carboplatin, Cisplatin, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Leucovorin, Methotrexate, Temozolomide, Vincristine
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

NCT01373151
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-945429 Placebo, BMS-945429, Methotrexate, Methotrexate Placebo, Adalimumab Placebo, Adalimumab
Drug · Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
13
States / cities
Peoria, Arizona • San Diego, California • Trumbull, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

NCT00175877
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
19
States / cities
Huntsville, Alabama • San Diego, California • Danbury, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

NCT00160641
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
12
States / cities
Palm Desert, California • Pasadena, California • Santa Maria, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy

NCT00689728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
LY2127399, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Birmingham, Alabama • Mesa, Arizona • Palm Desert, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Jun 26, 2026, 2:41 AM EDT
Terminated Phase 1 Interventional

Curcuma Longa L in Rheumatoid Arthritis

NCT02543931
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Meriva, placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

NCT00520572
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AZD9056, Etanercept, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Aventura, Florida • Orlando, Florida • Sarasota, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 3 Interventional

Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis

NCT00036153
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tacrolimus (Prograf®), Methotrexate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
42
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 4 Interventional Results available

Triple Combination Therapy in High Risk Crohn's Disease (CD)

NCT02764762
View directory record Official record
Conditions
Crohn Disease
Interventions
Vedolizumab, Adalimumab, Methotrexate
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
27
States / cities
Dothan, Alabama • Clearwater, Florida • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 3 Interventional

Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia

NCT00005945
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
3,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
116
States / cities
Phoenix, Arizona • Downey, California • Duarte, California + 92 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma

NCT00586846
View directory record Official record
Conditions
Osteosarcoma
Interventions
Cisplatin, Doxorubicin, Methotrexate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis

NCT02309359
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ALX-0061, Placebo, Methotrexate
Biological · Other · Drug
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years to 74 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Hemet, California • La Palma, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient

NCT01871961
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Methotrexate (Metoject® prefilled pen)
Drug
Lead sponsor
medac GmbH
Industry
Eligibility
16 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

NCT00813124
View directory record Official record
Conditions
Stem Cell Transplantation, Leukemia
Interventions
Fludarabine, Busulfan, Thymoglobulin, Azacitidine, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine

NCT05445440
View directory record Official record
Conditions
Healthy Participants
Interventions
Methotrexate, Leucovorin, BMS-986371, Sulfasalazine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 4 Interventional Results available

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

NCT02187055
View directory record Official record
Conditions
Rhematoid Arthritis
Interventions
Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
60
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jun 26, 2026, 2:41 AM EDT
Terminated Phase 2 Interventional

BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)

NCT00523328
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BG9924
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Jun 26, 2026, 2:41 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

NCT00406419
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Not applicable Interventional

Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate

NCT00018967
View directory record Official record
Conditions
Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
glucarpidase
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
88
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 80 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jun 26, 2026, 2:41 AM EDT
Recruiting Phase 3 Interventional

A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

NCT07388498
View directory record Official record
Conditions
Uncontrolled Gout
Interventions
Pegloticase, Methotrexate
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
52
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tustin, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jun 26, 2026, 2:41 AM EDT
Terminated Phase 4 Interventional

Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis

NCT00233558
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
adalimumab (up to 9 months exposure), methotrexate
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2007 · Synced Jun 26, 2026, 2:41 AM EDT
Not listed Phase 3 Interventional

Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics

NCT03535402
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab
Drug
Lead sponsor
Gaylis, Norman B., M.D.
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Jun 26, 2026, 2:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT

NCT00506922
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Pentostatin, Tacrolimus, Methotrexate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Jun 26, 2026, 2:41 AM EDT